Cardiovascular disease
Conditions
Interventions
Case series:NV
Sponsors
Shanghai Tenth People's Hospital
Eligibility
Sex/Gender
All
Age
35 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1) Inclusion criteria for patients with coronary heart disease The diagnosis conforms to the 2018 Guidelines for the Diagnosis and Treatment of Stable Coronary Heart Disease, the 2015 Guidelines for the Diagnosis and Treatment of Acute STEMI or the 2016 Guidelines for the Diagnosis and Treatment of Non STEMI; Age 35-75; Medication for coronary heart disease>6 months; Can correctly understand and explain their own medication. 2) Inclusion criteria for patients with heart failure The diagnosis was in accordance with the 2018 Chinese Guidelines for the Diagnosis and Treatment of Heart Failure; Age 35-75; Receive corresponding drug treatment > 6 months; Can correctly understand and explain their own medication. 3) Inclusion criteria for patients with atrial fibrillation Diagnosis in line with atrial fibrillation: current understanding and treatment recommendations - 2018; Age 35-75; Warfarin/rivasaban/dabigatran ester treatment>6 months; Can correctly understand and explain their own medication.
Exclusion criteria
Exclusion criteria: Acute pericardial tamponade, stent thrombosis, malignant arrhythmia, trauma, severe infection, severe bleeding, pulmonary embolism, cerebral infarction, shock, severe acid-base imbalance and water electrolyte disorder, severe liver and kidney dysfunction, severe ascites, hyperthyroid crisis, severe hypertension, diabetes, tuberculosis, malignant tumor and other diseases, previous psychiatric history or severe cognitive impairment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Age;Sex;Height;Weight;Marital status;Type of medical insurance;Disease;Hospitalization expenses;Hospitalization days;Smoke;Drink;City;Family history;Live alone;Using the network;Education level;Work activity;Exercise duration;Sleep duration;Age of onset;Disease duration;Comorbidities;Type of daily medication;Daily dosing frequency;Side effects;The scale of EQ-5D-5L;The scale of MMAS-8;State; | — |
Countries
China
Contacts
Public ContactWang JiNing
Outcome results
None listed